X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
oncology (13) 13
female (11) 11
index medicus (11) 11
aged (10) 10
cancer (10) 10
colorectal cancer (10) 10
male (10) 10
middle aged (10) 10
adult (8) 8
chemotherapy (7) 7
metastasis (7) 7
analysis (6) 6
clinical trials (6) 6
research (6) 6
care and treatment (5) 5
disease-free survival (5) 5
hematology, oncology and palliative medicine (5) 5
oxaliplatin (5) 5
aged, 80 and over (4) 4
colorectal neoplasms - drug therapy (4) 4
colorectal neoplasms - genetics (4) 4
colorectal neoplasms - mortality (4) 4
drug combinations (4) 4
oncology, experimental (4) 4
therapy (4) 4
adenocarcinoma - drug therapy (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
bevacizumab (3) 3
biomarkers, tumor - genetics (3) 3
capecitabine (3) 3
colorectal neoplasms - pathology (3) 3
fluorouracil (3) 3
kaplan-meier estimate (3) 3
kras (3) 3
medical colleges (3) 3
mutation (3) 3
neoplasm staging (3) 3
patients (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
ras proteins - genetics (3) 3
stomach neoplasms - drug therapy (3) 3
treatment outcome (3) 3
trial (3) 3
1st-line therapy (2) 2
5-fluorouracil (2) 2
adenocarcinoma (2) 2
adenocarcinoma - mortality (2) 2
adenocarcinoma - secondary (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents - therapeutic use (2) 2
appetite (2) 2
biomarker (2) 2
braf (2) 2
braf mutation (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
cancer research (2) 2
cancer therapies (2) 2
cetuximab (2) 2
cisplatin (2) 2
cisplatin - administration & dosage (2) 2
colorectal carcinoma (2) 2
combination (2) 2
digestive system diseases (2) 2
double-blind method (2) 2
esophageal cancer (2) 2
esophagus (2) 2
fluorouracil - adverse effects (2) 2
follow-up studies (2) 2
gastric cancer (2) 2
gastroenterology & hepatology (2) 2
health aspects (2) 2
hyponatremia - chemically induced (2) 2
intravenous administration (2) 2
japan - epidemiology (2) 2
leucovorin (2) 2
leucovorin - administration & dosage (2) 2
medical prognosis (2) 2
metastases (2) 2
neoplasms (2) 2
neutropenia (2) 2
organoplatinum compounds - administration & dosage (2) 2
oxonic acid - administration & dosage (2) 2
oxonic acid - adverse effects (2) 2
product development (2) 2
prognosis (2) 2
prognostic factor (2) 2
progression-free survival (2) 2
proportional hazards models (2) 2
proteins (2) 2
proto-oncogene proteins - genetics (2) 2
proto-oncogene proteins p21 (2) 2
ras mutation (2) 2
ras mutations (2) 2
research article (2) 2
stomach cancer (2) 2
stomach neoplasms - mortality (2) 2
studies (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 11, pp. 1063 - 1069
Summary Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but promising findings have been reported with irinotecan plus... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | 5-FLUOROURACIL | ONCOLOGY | HIGH-DOSE METHOTREXATE | DOXORUBICIN | ADVANCED ESOPHAGOGASTRIC CANCER | COOPERATIVE GROUP | EUROPEAN-ORGANIZATION | 1ST-LINE THERAPY | III TRIAL | CHEMOTHERAPY | Japan - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - secondary | Cisplatin - administration & dosage | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Time Factors | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Administration, Oral | Tegafur - adverse effects | Tegafur - therapeutic use | Proportional Hazards Models | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Oxonic Acid - adverse effects | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Infusions, Intravenous | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Information services | Research | Metastasis | Stomach cancer | Information services industry | Cancer | Fluorouracil | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 631 - 639
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
by Scholten, Olaf and van den Berg, Aiaan and Las Cumbres Observatory Grp and ATCA Australia Telescope and LIGO Sci Collaboration & Virgo and KU Collaboration and GROUND and RIMAS RATIR and AGILE Team and ASKAP Australian SKA Pathfinder and IPN Collaboration and LOFAR Collaboration and Salt Grp and VINROUGE Collaboration and Nordic Optical Telescope and MAXI Team and Fermi GBM and Fermi Large Area Telescope and J-GEM and IceCube Collaboration and BOOTES Collaboration and Pi Sky Collaboration and Pan-STARRS and LWA Long Wavelength Array and SKA South Africa MeerKAT and CALET Collaboration and AstroSat Cadmium Zinc Telluride and HAWC Collaboration and GROWTH JAGWAR CALTECH and ATLAS and ePESSTO and DFN Desert Fireball Network and Insight-Hxmt Collaboration and Texas Tech Univ and MASTER Collaboration and TZAC Consortium and Dark Energy Camera GW-EM and GRAWITA GRAvitational Wave and INTERGRAL and Toros Transient Robotic Observat and Chandra Team McGill Univ and H E S S Collaboration and Swift Collaboration and Pierre Auger Collaboration and OzGrav DWF Deeper Wider Faster and IKI-GW Follow-up Collaboration and Euro VLBI Team and High Time Resolution Universe and ANTARES Collaboration and DLT40 Collaboration and ALMA Collaboration and The 1M2H Team and MWA Murchison Widefield Array and The Insight-HXMT Collaboration and The MAXI Team and The Swift Collaboration and The Fermi Large Area Telescope Collaboration and GROND and TOROS: Transient Robotic Observatory of the South Collaboration and Texas Tech University and OzGrav, DWF (Deeper, Wider, Faster program), AST3, and CAASTRO Collaborations and MWA: Murchison Widefield Array and GROWTH, JAGWAR, Caltech-NRAO, TTU-NRAO, and NuSTAR Collaborations and INTEGRAL and RIMAS and RATIR and Pi of the Sky Collaboration and The Chandra Team at McGill University and LWA: Long Wavelength Array and The DLT40 Collaboration and DFN: Desert Fireball Network and LIGO Scientific Collaboration and Virgo Collaboration and ASKAP: Australian SKA Pathfinder and AstroSat Cadmium Zinc Telluride Imager Team and The BOOTES Collaboration and The Pierre Auger Collaboration and ATCA: Australia Telescope Compact Array and SALT Group and H.E.S.S. Collaboration and The Dark Energy Camera GW-EM Collaboration and the DES Collaboration and High Time Resolution Universe Survey and Las Cumbres Observatory Group and GRAWITA: GRAvitational Wave Inaf TeAm and The VINROUGE Collaboration and The CALET Collaboration and SLAC National Accelerator Lab., Menlo Park, CA (United States) and Brookhaven National Lab. (BNL), Upton, NY (United States) and Los Alamos National Lab. (LANL), Los Alamos, NM (United States) and Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States) and Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States) and Lawrence Berkeley National Laboratory-National Energy Research Scientific Computing Center (NERSC) and Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States) and Fysikum and Naturvetenskapliga fakulteten and Institutionen för astronomi and Stockholms universitet and Oskar Klein-centrum för kosmopartikelfysik (OKC)
Astrophysical Journal Letters, ISSN 2041-8205, 10/2017, Volume 848, Issue 2, p. L12
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2015, Volume 21, Issue 4, pp. 1275 - 1283
Journal Article
British Journal of Cancer, ISSN 0007-0920, 11/2017, Volume 117, Issue 10, pp. 1450 - 1458
Journal Article
Journal Article
Journal Article